Cardiogenic Shock Registry Mannheim

NCT ID: NCT05575856

Last Updated: 2022-10-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to investigate clinically and prognostically relevant parameters in patients with cardiogenic shock within a monocentric observational clinical register.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All consecutive patients with a confirmed cardiogenic shock presenting at the internal intensive care Unit (ICU) at the University of Mannheim are included in the register and followed up during ICU stay and after that. Data of patients' admission status, cause of cardiogenic shock, baseline parameters and comorbidities are collected. Extensive information about echocardiography, electrocardiography and imaging procedures are included in the register. Laboratory values, microbiological investigations, organ dysfunction and organ replacement therapies, medication, adverse events, and complications were recorded for several days during the ICU stay (days 1, 2, 3, 5, 7, and 8). Standard scores for critically ill patients were calculated for the day of admission at the ICU if available, and several time points during the ICU stay. The register includes information about the mortality during ICU stay, 30-day mortality, 6-month mortality and 1-year mortality.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiogenic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cardiogenic shock according to current guidelines

Exclusion Criteria

* other forms of shock not primary associated with cardiac dysfunction
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitätsmedizin Mannheim

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Behnes

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Department of Medicine, University Medical Centre Mannheim

Mannheim, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Behnes, PhD

Role: CONTACT

0049621-3836239

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ibrahim Akin, MD, PhD

Role: primary

0049621-3836239

Michael Behnes, MD, PhD

Role: backup

0049621-3836239

References

Explore related publications, articles, or registry entries linked to this study.

Rusnak J, Schupp T, Weidner K, Ruka M, Egner-Walter S, Schmitt A, Akin M, Tajti P, Mashayekhi K, Ayoub M, Behnes M, Akin I. Prognostic Influence of Lung Compliance in Patients with Cardiogenic Shock and Invasive Mechanical Ventilation. Rev Cardiovasc Med. 2024 Nov 22;25(11):420. doi: 10.31083/j.rcm2511420. eCollection 2024 Nov.

Reference Type DERIVED
PMID: 39618866 (View on PubMed)

Rusnak J, Schupp T, Weidner K, Ruka M, Egner-Walter S, Forner J, Schmitt A, Akin M, Tajti P, Mashayekhi K, Ayoub M, Akin I, Behnes M. Influence of Right and Left Bundle Branch Block in Patients With Cardiogenic Shock and Cardiac Arrest. Crit Care Med. 2025 Jan 1;53(1):e54-e64. doi: 10.1097/CCM.0000000000006459. Epub 2024 Oct 29.

Reference Type DERIVED
PMID: 39470337 (View on PubMed)

Schupp T, Rusnak J, Forner J, Dudda J, Bertsch T, Behnes M, Akin I. Platelet Count During Course of Cardiogenic Shock. ASAIO J. 2024 Jan 1;70(1):44-52. doi: 10.1097/MAT.0000000000002066. Epub 2023 Oct 12.

Reference Type DERIVED
PMID: 37831815 (View on PubMed)

Behnes M, Rusnak J, Egner-Walter S, Ruka M, Dudda J, Schmitt A, Forner J, Mashayekhi K, Tajti P, Ayoub M, Weiss C, Akin I, Schupp T. Effect of Admission and Onset Time on the Prognosis of Patients With Cardiogenic Shock. Chest. 2024 Jan;165(1):110-127. doi: 10.1016/j.chest.2023.08.011. Epub 2023 Aug 12.

Reference Type DERIVED
PMID: 37579943 (View on PubMed)

Schmitt A, Schupp T, Rusnak J, Ruka M, Egner-Walter S, Mashayekhi K, Tajti P, Ayoub M, Behnes M, Akin I, Weidner K. Does sex affect the risk of 30-day all-cause mortality in cardiogenic shock? Int J Cardiol. 2023 Jun 15;381:105-111. doi: 10.1016/j.ijcard.2023.03.061. Epub 2023 Mar 31.

Reference Type DERIVED
PMID: 37004944 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-695N

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CTO-PCI in Heart Failure Patients
NCT05632653 NOT_YET_RECRUITING NA
Fontan-Sprechstunde
NCT05563376 RECRUITING NA